- About Us
Mr. Blickenstaff has served as the president and chief executive officer of Tandem Diabetes Care, Inc., a privately held medical device company, since 2007. Prior to joining Tandem, Mr. Blickenstaff served as president, chief executive officer and co-founder of Biosite Incorporated. In addition, he has held various positions in finance, operations, research management, sales management, strategic planning and marketing with Baxter Travenol, National Health Laboratories and Hybritech Incorporated. He also serves as a director of several privately-held medical products companies. Mr. Blickenstaff received a B.A. and an M.B.A. from Loyola University, Chicago.
Ms. Falberg previously served as the Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc. She also served as its Senior Vice President and Chief Financial Officer from 2009 to 2012. From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. From 2001 through 2009, Ms. Falberg worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant. Ms. Falberg currently serves on the board, and is Chair of the Audit Committee, of biopharmaceutical company Halozyme Therapeutics, Inc.
Dr. Hung is a co-founder of Medivation and served as president, chief executive officer and director of Medivation Neurology since its inception in September 2003. He became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of Pro-Duct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. Pro-Duct Health, Inc. was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs. From 1996 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College.
Retired Senior Vice President/ Advisor to the Chairman, President and Chief Executive Officer, Merck & Co., Inc.
Dr. King has served on our board of directors since December 2015. Dr. King is a member of our Nominating and Corporate Governance Committee. Dr. King is currently a professor of practice at the University of Virginia School of Engineering and Applied Science and is an independent consultant to the pharmaceutical and biologics/vaccine industries, serving as a subject matter expert on chemistry, manufacturing and controls. Dr. King retired in 2007 from Merck & Co, Inc., following a 32-year career there focused on the commercialization, manufacturing and supply of vaccine and pharmaceutical products, where he most recently served as senior vice president / advisor to the chairman, president and chief executive officer. In that role, he provided assistance and leadership to facilitate implementation of Merck’s corporate strategy. Prior to that role, he served as senior vice president, science and technology, Merck Manufacturing Division. Dr. King received his Ph.D., in chemical engineering from the University of Delaware, a M.S., in chemical engineering from the University of Virginia, and a B.S., in Chemical Engineering from Virginia Tech. He also serves on the board of directors and advisory boards of multiple organizations.
Mr. Machado is a co-founder of Medivation and served as chief financial officer of Medivation Neurology since its inception in September 2003. He became chief financial officer of Medivation, Inc., when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004 and became chief business officer in December 2009. Mr. Machado retired from Medivation in April 2014. From 1998 until 2001, Mr. Machado was employed by Pro-Duct Health, Inc., a privately held medical device company, as vice president, chief financial officer and general counsel (1998-2000) and as senior vice president and chief financial officer (2000-2001). From 2001 until 2002, Mr. Machado served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation's acquisition of Pro-Duct Health, Inc. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University. Mr. Machado serves on the board and audit committee of Chimerix, Inc, a publicly traded biopharmaceutical company, and is chair of the board of Armaron Bio Pty Ltd, a privately held biopharmaceutical company.
Ms. Svoronos has served on our board of directors since April 2013. She retired in 2011 from Merck & Co., Inc. following a 23-year career there in commercial positions of increasing seniority, most recently a President of Europe and Canada. In that role, Ms. Svoronos had full P&L responsibility for 30 European markets with annual sales of several billion dollars and an employee base of several thousand. Prior to those roles, she served as Vice President, Asia Pacific for Merck. In 2009, Ms. Svoronos was elected as One of the Most Powerful Women in Canada by the Canadian Women’s Executive Network. Ms. Svoronos received a B.A. in English and French Literature from Carleton University. We recruited Ms. Svoronos to our board based on her extensive experience in commercialization of pharmaceutical products, including her substantial ex-U.S. commercialization expertise.
Mr. Vernon has served on our board of directors since 2006. He served as senior advisor to Kraft Foods Group, Inc. from January 2015 through March 2015, and chief executive officer for Kraft Foods Group, Inc. (2012-2014). Mr. Vernon previously served as the executive vice president and president of Kraft Foods North America (2009-2012). He came to Kraft Foods from private equity firm Ripplewood Holdings, where he served since 2006 as healthcare industry partner. Prior to Ripplewood Holdings, Mr. Vernon led a number of Johnson and Johnson's largest franchises during a 23 year career, including company group chairman of DePuy Orthopedics, Inc. (2004-2005), president of Centocor, Inc. (2001-2004), president of McNeil Consumer Healthcare (1999-2001), and president worldwide of the Johnson & Johnson Merck Joint Venture (1995-1999). Mr. Vernon received a B.A. from Lawrence University and an M.B.A. from the Northwestern University Kellogg Graduate School of Management.
Ms. Yarno has served on our Board since April 2013. Ms. Yarno is currently the Chair of our Compensation Committee and a member of our Audit Committee. Ms. Yarno retired in September 2008 from Merck & Co., Inc. following a 26-year career in commercial and human resource positions of increasing seniority, most recently Chief Marketing Officer before she retired. In that role, Ms. Yarno led a global organization charged with all aspects of supporting pre- and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. Prior to this role, she served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, where she had P&L responsibility for Merck’s largest therapeutic area, and as Senior Vice President, Human Resources. After retiring from Merck, Ms. Yarno worked part-time as the Chief Marketing Officer of HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, from September 2010 through September 2011. Ms. Yarno has served as a director of St. Jude Medical, Inc., a Fortune 500 medical device company, since 2002, Aratana Therapeutics, a biopharmaceutical company developing medicines for pets, since October 2013, and Durata Therapeutics, Inc., a pharmaceutical company, from August 2014 to November 2014 when it was acquired by Actavis W.C. Holding Inc. Ms. Yarno received a B.S. in Business Administration from Portland State University and an M.B.A from Temple University. We recruited Ms. Yarno to our Board based on her extensive experience in commercialization of pharmaceutical products and in human resource management in the pharmaceutical industry.Top